Zura Bio's FY net loss widens on higher R&D costs

Zura Bio

19/03/2026 20:33

Overview

U.S. immunology drug developer's FY 2025 net loss widened due to higher R&D expenses

Company completed $144 mln public offering in Feb 2026 to bolster cash position

Cash expected to fund planned operations through at least end of 2028

Outlook

Topline data from Phase 2 TibuSHIELD study in HS expected in Q4 2026

Topline data from Phase 2 TibuSURE study in SSc expected in first half of 2027

Company expects cash position to support operations through at least end of 2028

Result Drivers

R&D SPENDING - Higher research and development expenses driven by advancement of Phase 2 tibulizumab clinical programs, including increased payments to contract research and manufacturing organizations

G&A COSTS - General and administrative expenses rose due to higher costs to support company growth and advancement of clinical programs

ACCRUED OBLIGATION REVERSAL - R&D expense increase was partially offset by reversal of $5 mln accrued obligation after BAFFX17 Settlement and Release Agreement

Company press release: ID:nBw2FMv3Da

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
FY EPS
-$1.06
FY Net Income
-$68.65 mln
FY Income from Operations
-$75.25 mln
FY Operating Expenses
$75.25 mln
FY Pretax Profit
-$68.65 mln


Analyst Coverage

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 8 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Zura Bio Ltd is $15.00, about 150.4% above its March 18 closing price of $5.99

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)